The global Acute Myeloid Leukemia (AML) therapeutics market is projected to grow from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, registering a compound annual growth rate (CAGR) of 9.2%, according to a new report from Fact.MR. The market is expected to create an absolute dollar opportunity of approximately USD 5.9 billion, expanding nearly 2.4 times its value over the forecast period. This growth trajectory reflects the increasing shift toward genomics-driven treatment strategies, targeted therapies, and personalized medicine approaches that are transforming the management of acute myeloid leukemia worldwide.
As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, AML therapeutics are evolving from traditional chemotherapy-focused regimens toward highly individualized treatment pathways designed to improve patient outcomes and reduce disease recurrence. Targeted therapies are expected to account for 36% of market share in 2026, making them the largest drug class segment within the AML therapeutics market. The increasing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes.
By disease type, newly diagnosed AML is projected to hold 48% market share in 2026, as initial treatment regimens generate the highest therapy volumes. Hospitals remain the leading end-user segment, accounting for 55% of market demand, while hospital pharmacies maintain a dominant position with 49% market share due to the complexity of AML therapies. One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML patients, including new oral targeted therapies, menin inhibitors, and mutation-specific treatments.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR: "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations."
Regionally, South Asia and East Asia are emerging as high-growth areas due to expanding cancer care infrastructure and increasing access to molecular diagnostics. India is projected to grow at 11.8% CAGR, China at 10.9% CAGR, the United States at 8.7% CAGR, Germany at 7.9% CAGR, and Japan at 7.4% CAGR. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending.
Key companies operating in the market include AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. Industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, and clinical trials. For more details, access the full report at Fact.MR's AML Therapeutics Report or request a sample at this link.
The future of the AML therapeutics market will be shaped by continued advances in precision oncology, molecular diagnostics, and lower-intensity treatment regimens. While challenges related to treatment costs and reimbursement constraints remain, the long-term outlook remains highly positive as innovation reshapes the global hematology treatment landscape.
